semaglutide in percentage weight change and weight reduction targets of 10%, 15%, 20%, and 25% at 72 weeks [7]
"We are witnessing important innovations in medically-supervised weight loss," David Goldhill, Sesame's co-founder and CEO, said Tuesday in a news release
[1] Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
Glucose-dependent Insulinotropic Peptide (GIP): GIP also helps regulate insulin levels and plays a role in fat metabolism
However, side effects such as constipation and slowed digestion may increase flare risk in susceptible individuals
Some speculative mechanisms such as immunomodulatory effects of GLP-1 receptor agonism or indirect effects of significant weight loss on infection susceptibility have been raised in preclinical research, but there is currently no robust human clinical evidence linking these mechanisms to meaningful changes in UTI risk